Streetbeat News

PODD

Insulet Corporation

https://www.insulet.com

Industry

Medical - Devices

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Open

259.39

Mkt cap

18B

Volume

428K

High

265.26

P/E Ratio

44.56

52-wk high

279.40

Low

259.18

Div yield

N/A

52-wk low

160.19

Insulet (NASDAQ:PODD) reported Q4 2023 adjusted EPS of $1.40, surpassing the $0.66 estimate, with sales of $509.80M exceeding the $461.05M forecast. This represents a 37.90% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 9:09 pm

Nvidia's impressive earnings report has sparked optimism in the market, leading to a jump in Nasdaq and S&P 500 futures. Investors are now focused on upcoming economic data, including jobless claims and Fed speeches, to gauge the market's direction. Other stocks mentioned include Five9, Lucid Group, Rivian Automotive, Sunnova Energy, and Sunrun, which moved on their earnings reports. Additionally, several companies are set to report their quarterly results.

Portfolio Pulse from Shanthi Rexaline

February 22, 2024 | 12:23 pm

Earnings reports for various companies are scheduled for February 22, 2024, covering a wide range of industries. These reports include both earnings per share and revenue forecasts, with some companies expected to report losses.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 10:27 am

Insulet has received CE Mark approval for the compatibility of the Abbott FreeStyle Libre 2 Plus sensor with its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older under the European Medical Device Regulation.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 11:42 am

Stifel analyst Mathew Blackman has maintained a Hold rating on Insulet (NASDAQ:PODD) and increased the price target from $163 to $208. This adjustment reflects a more optimistic outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:11 pm

Insulet Corporation's stock (PODD) is trading higher following an upgrade from Baird, changing its rating from Neutral to Outperform. Baird also increased the price target for Insulet from $180 to $238.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 4:05 pm

Several top Wall Street analysts have updated their price targets and ratings for various US-listed companies. Morgan Stanley raised Regency Centers Corporation's target and upgraded the stock. Wedbush increased Amazon.com's price target while maintaining an Outperform rating. Wells Fargo lowered argenx SE's target but kept an Overweight rating. Deutsche Bank raised Micron Technology's target and maintained a Buy rating. HC Wainwright & Co. increased Immunovant's target with a Buy rating. Needham raised CrowdStrike Holdings' target and maintained a Buy rating. Morgan Stanley increased Salesforce's target and upgraded the stock. Pivotal Research raised Spotify Technology's target and upgraded the stock. Baird raised Insulet Corporation's target and upgraded the stock. JP Morgan raised Glaukos Corporation's target and upgraded the stock. All mentioned stocks experienced a decline in their share prices on Wednesday.

Portfolio Pulse from Avi Kapoor

December 21, 2023 | 12:36 pm

Insulet (NASDAQ:PODD) has been analyzed by 7 analysts, showing a range of opinions. The average 12-month price target is $213.29, with a high of $250 and a low of $162, marking a 13.71% decrease in the average target. Analysts from firms like Baird, Morgan Stanley, Piper Sandler, JP Morgan, Leerink Partners, and Jefferies have adjusted their ratings and price targets. Insulet's financials show strong revenue growth and ROE, but a high debt-to-equity ratio and below-average net margin.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 12:00 pm

Baird analyst Jeff Johnson upgraded Insulet (NASDAQ:PODD) from Neutral to Outperform and increased the price target from $180 to $238, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 10:15 am

Over the past quarter, Insulet (NASDAQ:PODD) received 8 analyst ratings, with 1 bullish, 5 somewhat bullish, and 2 indifferent. The average 12-month price target for Insulet is $212.25, with a high of $250.00 and a low of $162.00. This average has decreased by 20.63% from the previous average price target of $267.43. Analysts rate stocks based on company financials, meetings, and insider information, providing guidance to investors.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 1:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.